TABLE
Group I: Agents associated with the greatest number of NSF cases:
Gadodiamide (Omniscan® – GE Healthcare)
Gadopentetate dimeglumine (Magnevist® – Bayer HealthCare Pharmaceuticals)
Gadoversetamide (OptiMARK® – Covidien)
Group II: Agents associated with few, if any, unconfounded cases of NSF:
Gadobenate dimeglumine (MultiHance® – Bracco Diagnostics)
Gadoteridol (ProHance® – Bracco Diagnostics)
Gadoteric acid (Dotarem® – Guerbet [as of this writing not FDA-approved for use in the U.S.]
Gadobutrol (Gadavist® – Bayer HealthCare Pharmaceuticals)
Group III: Agents that have only recently appeared on the market:
Gadofosveset (Ablavar® – Lantheus Medical Imaging)
Gadoxetic acid (Eovist® – Bayer HealthCare Pharmaceuticals)
There is limited data for group III agents, although, to date, few, if any, unconfounded cases of NSF
have been reported.